Hui Hao-Shen

TL;DR: Surprisingly, the number of mutations between early and late patient samples did not significantly change, and during a total follow-up of 133 patient years, only 2 new mutations appeared, suggesting that the mutation rate in MPN is rather low.

TL;DR: Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis, consistent with the hypothesis that the ratio of mutant to wild-type JAK1 is critical for the phenotypic manifestation.

TL;DR: In this article, the authors generated JAK2-V617F transgenic mice with the sequences encoding the kinase domain placed in the inverse orientation and flanked by antiparallel loxP sites.

TL;DR: To generate transgenic mice that express Cre-recombinase exclusively in the megakaryocytic lineage, a mouse bacterial artificial chromosome clone is modified and the first exon of the platelet factor 4 (Pf4), also called CXCL4, is replaced with a codon-improved Cre cDNA.

TL;DR: In 4 of 8 myeloproliferative neoplasm patients, it was found that some colonies with mutated TET2 carried wild-type JAK2, whereas others wereJAK2-V617F positive, indicating that TET1 occurred before JAK1-V615F, and the lack of a strict temporal order of occurrence makes it unlikely that mutations in TET3 represent a predisposing event for acquiring mutations in JAK3.